Effects of Raloxifene on Bone Mineral Metabolism in Postmenopausal Japanese Women on Hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 15, Issue SUPPL.1, 2011, Pages 62-66

  Tanaka, Motoko ^a   Itoh, Kazuko ^a   Matsushita, Kazunori ^a   Matsushita, Kazutaka ^a   Moriishi, Misaki ^b   Kawanishi, Hideki ^b   Fukagawa, Masafumi ^c  

^a Akebono Clinic   (Japan)

^b TSUCHIYA GENERAL HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone mineral metabolism; Hemodialysis; Osteoporosis; Postmenopausal women; Raloxifene

Indexed keywords

CALCIUM SALT; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; JAPANESE; LUMBAR SPINE; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CASE-CONTROL STUDIES; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PHOSPHORUS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79956188816     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00929.x     Document Type: Article

References (21)

1. Eastell R. Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 2005;185:223-34.
2. Fukagawa M, Hamada Y, Nakanishi S, Tanaka M. The kidney and bone metabolism: Nephrologists' point of view. J Bone Miner Metab 2006;24:434-8.
3. Rossouw JE, Anderson GL, Prentice RL etal. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Anderson GL, Limacher M, Assaf AR etal. Effects of conjugated equine estrogen in healthy postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
5. Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M. High serum estradiol levels are detected in postmenopausal women with end-stage renal disease. Clin Nephrol 2005;64:394-6.
6. Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:109-22.
7. Fujii N, Hamano T, Mikami S etal. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 2007;22:1601-7.
8. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011;1218:38-46.
9. Delmas PD, Ensrud KE, Adachi JD etal.; Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17.
10. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002;175:319-27.
11. Barrett-Connor E, Grady D, Sashegyi A etal.; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
12. Hernández E, Valera R, Alonzo E etal. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003;63:2269-74.
13. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
14. Alem AM, Sherrard DJ, Gillen DL etal. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396-9.
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130.
16. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-25.
17. Iwasaki Y, Yamato H, Nii-Kono T etal. Uremic toxin and bone metabolism. J Bone Miner Metab 2006;24:172-5.
18. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003;14(Suppl 3):S13-8.
19. Ferechide D, Radulescu D. Hyperhomocysteinemia in renal diseases. J Med Life 2009;2:53-9.
20. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 2010;21:655-66.
21. Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008;19:1343-54.